FIMECS Presents at the 3rd Annual Targeted Protein Degradation Europe Summit

Kanagawa, Japan, 27th March 2023 – FIMECS, Inc. ("FIMECS"), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the results of its research on targeted protein degraders based on its platform technology, RaPPIDS™, will be presented at the 3rd Annual Targeted Protein Degradation Europe Summit (28-30 March 2023 in London, UK).

Title: Function-First Approach for Generation of Novel E3 Ligase Binders and Degraders by RaPPIDS™ Platform
Presenters: Yoshitaka Numajiri, Michiko Watanabe, Shinya Yokosaka, Tomoaki Hayashi, Kazuteru Aoki, Kanae Gamo, Yusuke Tominari
Time and date: 15:00-16:00 (local time), Wednesday, March 29, 2023

In this presentation, the identification and optimization of novel E3 ligase binding molecules by the "Function-First Approach" will be shown, utilizing its platform technology RaPPIDS™, which enables highly efficient synthesis and evaluation of numerous degraders.

For more information: https://tpd-europe.com/

About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently 'undruggable' targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/

About RaPPIDS™
RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company's proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS™ platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.

# # #

FIMECS, Inc. Media and Investor Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261

Email: info@fimecs.com